open access

Online first
Short communication
Published online: 2021-10-11
Get Citation

Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation Observational registry

Reinhold Kreutz1, Gilbert Deray2, Jürgen Floege3, Marianne Gwechenberger4, Kai Hahn5, Andreas R Luft6, Pontus Persson7, Jan Beyer-Westendorf8
DOI: 10.33963/KP.a2021.0134
·
Pubmed: 34643264
Affiliations
  1. Charité — Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Clinical Pharmacology and Toxicology, Germany
  2. Department of Nephrology, Pitié-Salpêtrière University Hospital, Paris, France
  3. Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Germany
  4. University Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria
  5. B Braun Medical Care AG Dialysezentrum Hochfelden, Zürich, Switzerland
  6. Klinik für Neurologie, Universitätsspital Zürich, Switzerland and cereneo — Center for Neurology and Rehabilitation, Vitznau, Switzerland
  7. Charité — Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für vegetative Physiologie,
  8. Thrombosis Research Unit, Department of Medicine I, Division Haematology, University Hospital Carl Gustav Carus Dresden, Dresden, Germany

open access

Online first
Short communication
Published online: 2021-10-11

Abstract

Not available

Abstract

Not available
Get Citation
Supp./Additional Files (1)
Supplementary material
Download
60KB
About this article
Title

Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation Observational registry

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Short communication

Published online

2021-10-11

DOI

10.33963/KP.a2021.0134

Pubmed

34643264

Authors

Reinhold Kreutz
Gilbert Deray
Jürgen Floege
Marianne Gwechenberger
Kai Hahn
Andreas R Luft
Pontus Persson
Jan Beyer-Westendorf

References (14)
  1. Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019; 74(17): 2204–2215.
  2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
  3. Weir MR, Kreutz R. Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non-vitamin K antagonist oral anticoagulants. Mayo Clin Proc. 2018; 93(10): 1503–1519.
  4. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
  5. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  6. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32(19): 2387–2394.
  7. Steffel J, Collins R, Antz M, et al. External reviewers. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23(10): 1612–1676.
  8. Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015; 65(23): 2481–2493.
  9. Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017; 70(21): 2621–2632.
  10. Undas A, Drabik L, Potpara T. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. Kardiologia Polska. 2020; 78(2): 105–116.
  11. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604–612.
  12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31–41.
  13. Collins GS, Le Manach Y. Comparing treatment effects between propensity scores and randomized controlled trials: improving conduct and reporting. Eur Heart J. 2012; 33(15): 1867–1869.
  14. Kreutz R, Camm AJ, Rossing P. Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. Eur Heart J Suppl. 2020; 22(Suppl O): O78–O86.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl